These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 23357841

  • 1. Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects.
    Zhuang Y, Xu Z, de Vries DE, Wang Q, Shishido A, Comisar C, Ford JA, Keen M, Achira M, Tsukamoto Y, Petty KJ, Davis HM, Zhou H.
    Int J Clin Pharmacol Ther; 2013 Mar; 51(3):187-99. PubMed ID: 23357841
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
    Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, Davis HM, Zhou H.
    Br J Clin Pharmacol; 2011 Aug; 72(2):270-81. PubMed ID: 21392075
    [Abstract] [Full Text] [Related]

  • 3. Absolute Bioavailability and Pharmacokinetic Comparability of Sirukumab Following Subcutaneous Administration by a Prefilled Syringe or an Autoinjector.
    Zhuang Y, de Vries DE, Marciniak SJ, Liu H, Zhou H, Davis HM, Leon F, Raible D, Xu Z.
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):570-576. PubMed ID: 28052588
    [Abstract] [Full Text] [Related]

  • 4. A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects.
    Cohen-Barak O, Weiss S, Rasamoelisolo M, Faulhaber N, Yeung PP, Loupe PS, Yoon E, Gandhi MD, Spiegelstein O, Aycardi E.
    Cephalalgia; 2018 Nov; 38(13):1960-1971. PubMed ID: 29667896
    [Abstract] [Full Text] [Related]

  • 5. Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects.
    Ling J, Lyn S, Xu Z, Achira M, Bouman-Thio E, Shishido A, Ford J, Shankar G, Wagner C, Kim KT, Davis HM, Zhou H.
    J Clin Pharmacol; 2010 Jul; 50(7):792-802. PubMed ID: 20133508
    [Abstract] [Full Text] [Related]

  • 6. Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid Arthritis.
    Xu Y, Hu C, Zhuang Y, Hsu B, Xu Z, Zhou H.
    J Clin Pharmacol; 2018 Jul; 58(7):939-951. PubMed ID: 29578578
    [Abstract] [Full Text] [Related]

  • 7. Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men
.
    Tanaka S, Harada S, Hiramatsu N, Nakaya R, Kawamura M.
    Int J Clin Pharmacol Ther; 2018 Nov; 56(11):507-517. PubMed ID: 30168415
    [Abstract] [Full Text] [Related]

  • 8. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
    Willen D, Uhl W, Wolna P, Papasouliotis O, Yalkinoglu Ö.
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406
    [Abstract] [Full Text] [Related]

  • 9. Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.
    van Hartingsveldt B, Nnane IP, Bouman-Thio E, Loza MJ, Piantone A, Davis HM, Petty KJ.
    Br J Clin Pharmacol; 2013 May; 75(5):1289-98. PubMed ID: 23043368
    [Abstract] [Full Text] [Related]

  • 10. A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects.
    Ermer J, Martin P, Corcoran M, Matsuo Y.
    Neuropsychopharmacol Rep; 2020 Mar; 40(1):16-29. PubMed ID: 31765110
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies.
    Zhu Y, Wang Q, Frederick B, Bouman-Thio E, Marini JC, Keen M, Petty KJ, Davis HM, Zhou H.
    Clin Drug Investig; 2013 Apr; 33(4):291-301. PubMed ID: 23512638
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis.
    Khatri A, Eckert D, Oberoi R, Suleiman A, Pang Y, Cheng L, Othman AA.
    J Clin Pharmacol; 2019 Dec; 59(12):1656-1668. PubMed ID: 31257614
    [Abstract] [Full Text] [Related]

  • 13. A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects.
    Jeon Y, Lee N, Baek S, Choi J, Jhee S, Lee H.
    Drugs R D; 2022 Mar; 22(1):71-87. PubMed ID: 34993933
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects.
    Shibata M, Hatta T, Saito M, Toyoshima J, Kaneko Y, Oda K, Nishimura T.
    Clin Drug Investig; 2020 May; 40(5):469-484. PubMed ID: 32274653
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and safety of golimumab in healthy Chinese subjects following a single subcutaneous administration in a randomized phase I trial.
    Zhuang Y, Lyn S, Lv Y, Xu Z, Bouman-Thio E, Masterson T, Ford JA, Keen M, Petty KJ, Davis HM, Zhou H.
    Clin Drug Investig; 2013 Nov; 33(11):795-800. PubMed ID: 23975656
    [Abstract] [Full Text] [Related]

  • 16. The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers.
    Shida Y, Takahashi N, Sakamoto T, Ino H, Endo A, Hirama T.
    J Clin Pharm Ther; 2014 Feb; 39(1):97-101. PubMed ID: 24117862
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.
    Cawello W, Kim SR, Braun M, Elshoff JP, Ikeda J, Funaki T.
    Clin Drug Investig; 2014 Feb; 34(2):95-105. PubMed ID: 24178238
    [Abstract] [Full Text] [Related]

  • 18. Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects.
    Morrison M, Palermo G, Schmitt C.
    Eur J Clin Pharmacol; 2015 Nov; 71(11):1365-74. PubMed ID: 26363899
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of repaglinide in healthy caucasian and Japanese subjects.
    Thomsen MS, Chassard D, Evène E, Nielsen KK, Jørgensen M.
    J Clin Pharmacol; 2003 Jan; 43(1):23-8. PubMed ID: 12520624
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.
    Miyachi N, Zagrijtschuk O, Kang L, Yonezu K, Qin A.
    Clin Drug Investig; 2021 Apr; 41(4):391-404. PubMed ID: 33725322
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.